+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Market Spotlight: Coronary Artery Disease

  • ID: 4775146
  • Report
  • June 2021
  • Region: Global
  • 35 Pages
  • Pharma Intelligence
This Market Spotlight report covers the Coronary Artery Disease (CAD) market, comprising key marketed and pipeline drugs, clinical trials, upcoming and regulatory events, probability of success, and 10-year disease prevalence and incidence forecasts, as well as presenting drug-specific revenue forecasts.

Key Takeaways
  • The publisher estimates that in 2017, there were approximately 327.9 million prevalent cases of coronary artery disease worldwide, and forecasts that number to increase to 365.9 million prevalent cases by 2026.
  • Coronary artery disease has a male predominance. Globally, the publisher estimates that in 2017, 58.65% of cases aged 15 years and over were male.
  • The publisher estimates that in 2017, there were approximately 9.5 million incident cases of acute coronary syndrome worldwide, and forecasts that number to increase to 10.7 million incident cases by 2026.
  • Acute coronary syndrome has a male predominance. Globally, the publisher estimates that in 2017, 63.78% of cases aged 25 years and over were male.
  • The approved drugs in the coronary artery disease space target angiotensin converting enzyme, amyloid beta/amyloid plaques, adenosine diphosphate P2Y12 receptor, calcium channel, and coagulation factor X. The majority of marketed drugs are administered via the oral route, with one product being available in an intravenous formulation.
  • The largest proportion of industry-sponsored drugs in active clinical development for coronary artery disease are in Phase II. Therapies in development for coronary artery disease focus on a variety of targets. These drugs are administered via the oral, subcutaneous, and percutaneous catheter/injection routes.
  • The only high-impact upcoming event in the coronary artery disease space is topline Phase IIa trial results for AZD5718. The overall likelihood of approval of a Phase I cardiovascular disease asset is 6.5%, and the average probability a drug advances from Phase III is 54.5%. Drugs, on average, take 10.1 years from Phase I to approval in the cardiovascular space.
  • There have been equal proportions of clinical trials for coronary artery disease across phases of development, with 50% in Phase I–II, and 50% in Phase III–IV.
  • The US has a substantial lead in the number of coronary artery disease clinical trials globally. Germany leads the major European markets, while China has the top spot in Asia.
  • Clinical trial activity in the coronary artery disease space is dominated by completed trials. Pfizer has the highest number of completed clinical trials for coronary artery disease, with 99 trials.
  • Pfizer leads industry sponsors with the highest overall number of clinical trials for coronary artery disease.
Note: Product cover images may vary from those shown
OVERVIEW

KEY TAKEAWAYS

DISEASE BACKGROUND

TREATMENT
  • Medical management
  • Medical procedures and surgery
  • Cardiac rehabilitation
EPIDEMIOLOGY

MARKETED DRUGS

PIPELINE DRUGS

KEY UPCOMING EVENTS

KEY REGULATORY EVENTS
  • Accord Gets First EU-Wide Nod For Xarelto Rival
  • SELUTION SLR 014 Addressing Coronary In-Stent Restenosis
  • NDAs And More: Recent Submissions For FDA Approval
  • AZ Takes Time To Answer EU Queries On Broadening Brilique Indication
  • Brilinta Approved To Reduce Risk Of First MI, Stroke In High-Risk CAD Patients
PROBABILITY OF SUCCESS

REVENUE OPPORTUNITY

CLINICAL TRIAL LANDSCAPE
  • Sponsors by status
  • Sponsors by phase
  • Recent events
BIBLIOGRAPHY

APPENDIX

LIST OF FIGURES
Figure 1: Trends in prevalent cases of coronary artery disease, 2017–26
Figure 2: Trends in incident cases of acute coronary syndrome, 2017–26
Figure 3: Overview of pipeline drugs for coronary artery disease in the US
Figure 4: Pipeline drugs for coronary artery disease, by company
Figure 5: Pipeline drugs for coronary artery disease, by drug type
Figure 6: Pipeline drugs for coronary artery disease, by classification
Figure 7: Key upcoming events in coronary artery disease
Figure 8: Probability of success in the cardiovascular pipeline
Figure 9: Clinical trials in coronary artery disease
Figure 10: Top 10 drugs for clinical trials in coronary artery disease
Figure 11: Top 10 companies for clinical trials in coronary artery disease
Figure 12: Trial locations in coronary artery disease
Figure 13: Coronary artery disease trials status
Figure 14: Coronary artery disease trials sponsors, by phase

LIST OF TABLES
Table 1: Prevalent cases of coronary artery disease, 2017–26
Table 2: Prevalent cases of coronary artery disease, by gender, 2017
Table 3: Incident cases of acute coronary syndrome, 2017–26
Table 4: Incident cases of acute coronary syndrome, by gender, 2017
Table 5: Marketed drugs for coronary artery disease
Table 6: Pipeline drugs for coronary artery disease in the US
Table 7: Historical global sales, by drug ($m), 2016–20
Table 8: Forecasted global sales, by drug ($m), 2021–25
Note: Product cover images may vary from those shown
Adroll
adroll